Publication
Portal Vein Embolization With N-Butyl-Cyanoacrylate Through an Ipsilateral Approach Before Major Hepatectomy: Single Center Analysis of 50 Consecutive Patients
| dc.contributor.author | Mendes Luz, JH | |
| dc.contributor.author | Mendes Luz, P | |
| dc.contributor.author | Bilhim, T | |
| dc.contributor.author | Martin, H | |
| dc.contributor.author | Gouveia, H | |
| dc.contributor.author | Coimbra, E | |
| dc.contributor.author | Veloso Gomes, F | |
| dc.contributor.author | Souza, R | |
| dc.contributor.author | Faria, I | |
| dc.contributor.author | Nepomuceno de Miranda, T | |
| dc.date.accessioned | 2017-11-06T12:13:13Z | |
| dc.date.available | 2017-11-06T12:13:13Z | |
| dc.date.issued | 2017-09-20 | |
| dc.description.abstract | PURPOSE: To evaluate the efficacy of portal vein embolization (PVE) with n-Butyl-cyanoacrylate (NBCA) through an ipsilateral approach before major hepatectomy. Secondary end-points were PVE safety, liver resection and patient outcome. METHODS: Over a 5-year period 50 non-cirrhotic consecutive patients were included with primary or secondary liver cancer treatable by hepatectomy with a liver remnant (FLR) volume less than 25% or less than 40% in diseased livers. RESULTS: There were 37 men and 13 women with a mean age of 57 years. Colorectal liver metastases were the most frequent tumor and patients were previously exposed to chemotherapy. FLR increased from 422 ml to 629 ml (P < 0.001) after PVE, corresponding to anincrease of 52%. The FLR ratio increased from 29.6% to 42.3% (P < 0.001). Kinetic growth rate was 2.98%/week. A negative association was observed between increase in the FLR and FLR ratio and FLR volume before PVE (P = 0.002). In 31 patients hepatectomy was accomplished and only one patient presented with liver insufficiency within 30 days after surgery. CONCLUSIONS: PVE with NBCA through an ipsilateral puncture is effective before major hepatectomy. Meticulous attention is needed especially near the end of the embolization procedure to avoid complications. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Cancer Imaging. 2017 Sep 20;17(1):25. | pt_PT |
| dc.identifier.doi | 10.1186/s40644-017-0127-3 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.17/2778 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | BioMed Central | pt_PT |
| dc.subject | HCC IMA | pt_PT |
| dc.subject | CHLC CHBPT | pt_PT |
| dc.subject | Combined Modality Therapy | pt_PT |
| dc.subject | Embolization, Therapeutic/methods | pt_PT |
| dc.subject | Enbucrilate/administration & dosage | pt_PT |
| dc.subject | Hepatectomy/methods | pt_PT |
| dc.subject | Liver Neoplasms/therapy | pt_PT |
| dc.subject | Portal Vein | |
| dc.subject | Treatment Outcome | |
| dc.title | Portal Vein Embolization With N-Butyl-Cyanoacrylate Through an Ipsilateral Approach Before Major Hepatectomy: Single Center Analysis of 50 Consecutive Patients | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 1 | pt_PT |
| oaire.citation.startPage | 25 | pt_PT |
| oaire.citation.title | Cancer Imaging | pt_PT |
| oaire.citation.volume | 17 | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |